Literature DB >> 21571363

Pirfenidone for idiopathic pulmonary fibrosis.

Demosthenes Bouros1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571363     DOI: 10.1016/S0140-6736(11)60546-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

Review 2.  Pirfenidone: in idiopathic pulmonary fibrosis.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

3.  Resident mesenchymal cells and fibrosis.

Authors:  Nicol Hutchison; Cécile Fligny; Jeremy S Duffield
Journal:  Biochim Biophys Acta       Date:  2012-12-04

4.  Paeoniflorin suppresses TGF-β mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway.

Authors:  Yu Ji; Yan-Nong Dou; Qian-Wen Zhao; Ji-Zhou Zhang; Yan Yang; Ting Wang; Yu-Feng Xia; Yue Dai; Zhi-Feng Wei
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

5.  Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Authors:  Argyris Tzouvelekis; George Koliakos; Paschalis Ntolios; Irene Baira; Evangelos Bouros; Anastasia Oikonomou; Athanassios Zissimopoulos; George Kolios; Despoina Kakagia; Vassilis Paspaliaris; Ioannis Kotsianidis; Marios Froudarakis; Demosthenes Bouros
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

Review 6.  The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.

Authors:  Giulia Maria Stella; Vito D'Agnano; Davide Piloni; Laura Saracino; Sara Lettieri; Francesca Mariani; Andrea Lancia; Chandra Bortolotto; Pietro Rinaldi; Francesco Falanga; Cristiano Primiceri; Angelo Guido Corsico; Andrea Bianco
Journal:  Transl Lung Cancer Res       Date:  2022-03

7.  A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Authors:  Argyris Tzouvelekis; Vassilis Paspaliaris; George Koliakos; Paschalis Ntolios; Evangelos Bouros; Anastasia Oikonomou; Athanassios Zissimopoulos; Nikolaos Boussios; Brian Dardzinski; Dimitrios Gritzalis; Antonis Antoniadis; Marios Froudarakis; George Kolios; Demosthenes Bouros
Journal:  J Transl Med       Date:  2013-07-15       Impact factor: 5.531

8.  Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Authors:  Argyrios Tzouvelekis; Theodoros Karampitsakos; Paschalis Ntolios; Vasilios Tzilas; Evangelos Bouros; Evangelos Markozannes; Ioanna Malliou; Aris Anagnostopoulos; Andreas Granitsas; Paschalis Steiropoulos; Katerina Dimakou; Serafeim Chrysikos; Nikolaos Koulouris; Demosthenes Bouros
Journal:  Front Med (Lausanne)       Date:  2017-11-29

Review 9.  Pirfenidone as a novel cardiac protective treatment.

Authors:  Alberto Aimo; Giosafat Spitaleri; Giorgia Panichella; Josep Lupón; Michele Emdin; Antoni Bayes-Genis
Journal:  Heart Fail Rev       Date:  2021-10-20       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.